Patents by Inventor Geetanjali Sharma

Geetanjali Sharma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity
    Patent number: 11963949
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: April 23, 2024
    Assignee: UNM RAINFOREST INNOVATIONS
    Inventors: Eric R. Prossnitz, Geetanjali Sharma, Matthias Barton, Matthias R. Meyer
  • METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY
    Publication number: 20210186936
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Inventors: Eric R. Prossnitz, Geetanjali Sharma, Matthias Barton, Matthias R. Meyer
  • Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity
    Patent number: 10980785
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: April 20, 2021
    Assignee: UNM Rainforest Innovations
    Inventors: Eric R. Prossnitz, Geetanjali Sharma, Matthias Barton, Matthias R. Meyer
  • METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY
    Publication number: 20200113875
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
    Type: Application
    Filed: September 20, 2019
    Publication date: April 16, 2020
    Inventors: Eric R. Prossnitz, Geetanjali Sharma, Matthias Barton, Matthias R. Meyer
  • Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity
    Patent number: 10471047
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: November 12, 2019
    Assignee: STC.UNM
    Inventors: Eric R. Prossnitz, Geetanjali Sharma
  • METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY
    Publication number: 20180318269
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
    Type: Application
    Filed: July 11, 2018
    Publication date: November 8, 2018
    Inventors: Eric R. Prossnitz, Geetanjali Sharma, Matthias Barton, Matthias R. Meyer
  • METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY
    Publication number: 20180055826
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
    Type: Application
    Filed: March 2, 2016
    Publication date: March 1, 2018
    Inventors: Eric R. Prossnitz, Geetanjali Sharma, Matthias Barton, Matthias R. Meyer